Liver Cancer is one of the few cancers whose rates in the US and around the world are rising instead of falling. Interventional radiology and interventional oncology therapies are essential ensuring that patients with liver cancer are diagnosed as early as possible so that they have every innovative option for survival available to them.
NASH has been called a “hidden epidemic.” Millions of people are at risk, yet people with the disease show no symptoms until the very late stages. Diagnosing the disease is also difficult as it can take decades to progress to advanced fibrosis and cirrhosis, and it can only be diagnosed with an invasive and painful liver biopsy. While there is a lot we don’t know about NASH, there are many things we do know.
Statistics show that as many as one-third of adults living with a chronic illness are at greater risk of contracting the potentially deadly pneumococcal disease. Worse, if a person living with liver disease contracts pneumococcal disease, the long-term potential for worsening of their disease is elevated.